Engineered pancreatic islet organoids encoding a polypeptide not endogenously expressed in pancreatic islet cells and methods for using them to treat diseases and disorders associated with reduced or absent expression of the polypeptide are provided.

This document provides butyrylcholinesterases having an enhanced ability to hydrolyze acyl ghrelin as well as nucleic acids encoding such butyrylcholinesterases. This document also provides methods and materials for treating obesity and/or aggression. For example, methods for administering a nucleic acid encoding a wild-type or mutant butyrylcholinesterase having the ability to hydrolyze acyl ghrelin to a mammal under conditions wherein the level of acyl ghrelin within the mammal is reduced, under conditions wherein the rate of body weight gain of the mammal is reduced, under conditions wherein the mammal's level of aggression is reduced, and/or under conditions wherein the mammal's rate of developing stress-induced tissue damage are provided.

The present disclosure relates to the identification of Nurr1 as a key regulator of metabolism, and the use of Nurr1 agonist to treat metabolic disorders such as diabetes, obesity, metabolic syndrome and hepatic steatosis.

The present disclosure relates to the identification of Nurr1 as a key regulator of metabolism, and the use of Nurr1 agonist to treat metabolic disorders such as diabetes, obesity, metabolic syndrome and hepatic steatosis.

Devices, methods and compositions for treating cardiovascular disorders are configured for sustained-release of leptin antagonist into a blood vessel in order to down-regulate an expression or activity of leptin in a cardiovascular tissue that is affected by a disorder.

Provided herein are methods of enhancing in vivo efficacy of an active agent, comprising: administering to a subject an active agent that is coupled to a bioelastic polymer or elastin-like peptide, wherein the in vivo efficacy of the active agent is enhanced as compared to the same active agent when administered to the subject not coupled to (or not associated with) a bioelastic polymer or ELP.

The present invention relates to exendin-4 derivatives and their medical use, for example in the treatment of disorders of the metabolic syndrome, including diabetes and obesity, as well as reduction of excess food intake.

The present invention relates to exendin-4 derivatives and their medical use, for example in the treatment of disorders of the metabolic syndrome, including diabetes and obesity, as well as reduction of excess food intake.

The present invention provides a plant expressing a target protein, a method of preparing the same and a method of preparing a composition for oral administration of a biopharmaceutical using the same. A target protein expression system using plant cells according to the present invention solves conventional problems in plant cell culture, provides a method of producing a large quantity of target proteins including a biopharmaceutical protein and allowing a target protein to have a resistance to a protease present in a digestive organ, and therefore is very effective to enable commercialization of plant-derived biopharmaceuticals.

A method and device for localized treatment of tissues or organs that were exposed to ischemia and reperfusion (IR) injury, in order to reduce their structural damage and loss of function. The method further includes intra-arterial treatment of transplanted tissues or organs, which are exposed to similar damage of IR and are at risk of impaired function. Leptin antagonist is administered as a bolus injection directly into a re-opened artery, which supplies blood to the tissue or organ involved, immediately after reperfusion. In some cases, after administering a bolus injection of leptin antagonist, the effect of leptin antagonist in the involved organ can be prolonged by deploying a double function drug eluting stent, which elutes leptin antagonist into the lumen, e.g., by sustained release, while eluting antiproliferative drug into the vessel wall to prevent local stenosis, which may appear due to stent deployment.